These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 31025329)
1. Confirmed case of Pneumocystis pneumonia in a Maltese Terrier × Papillon dog being treated with toceranib phosphate. Best MP; Boyd SP; Danesi P Aust Vet J; 2019 May; 97(5):162-165. PubMed ID: 31025329 [TBL] [Abstract][Full Text] [Related]
2. Skin depigmentation associated with toceranib phosphate in a dog. Cavalcanti JVJ; Hasbach A; Barnes K; Dange RB; Patterson J; Saavedra PV Vet Dermatol; 2017 Aug; 28(4):400-e95. PubMed ID: 28164401 [TBL] [Abstract][Full Text] [Related]
3. Toceranib phosphate-associated nephrotic syndrome in a dog: a case report. Remerowski SM; Herrera CL; Donnelly LL BMC Vet Res; 2021 Apr; 17(1):146. PubMed ID: 33827545 [TBL] [Abstract][Full Text] [Related]
4. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. London CA; Malpas PB; Wood-Follis SL; Boucher JF; Rusk AW; Rosenberg MP; Henry CJ; Mitchener KL; Klein MK; Hintermeister JG; Bergman PJ; Couto GC; Mauldin GN; Michels GM Clin Cancer Res; 2009 Jun; 15(11):3856-65. PubMed ID: 19470739 [TBL] [Abstract][Full Text] [Related]
5. Effects of Toceranib Phosphate on Systolic Blood Pressure and Proteinuria in Dogs. Tjostheim SS; Stepien RL; Markovic LE; Stein TJ J Vet Intern Med; 2016 Jul; 30(4):951-7. PubMed ID: 27149912 [TBL] [Abstract][Full Text] [Related]
6. Plasma cytokeratin-18 concentrations as noninvasive biomarker of early gastrointestinal toxicosis in dogs receiving toceranib. Kovac RL; Ballash G; Fenger J; London C; Warry E J Vet Intern Med; 2018 Nov; 32(6):2061-2068. PubMed ID: 30353992 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic properties of toceranib phosphate (Palladia, SU11654), a novel tyrosine kinase inhibitor, in laboratory dogs and dogs with mast cell tumors. Yancey MF; Merritt DA; Lesman SP; Boucher JF; Michels GM J Vet Pharmacol Ther; 2010 Apr; 33(2):162-71. PubMed ID: 20444041 [TBL] [Abstract][Full Text] [Related]
8. A retrospective study of proteinuria in dogs receiving toceranib phosphate. Piscoya SL; Hume KR; Balkman CE Can Vet J; 2018 Jun; 59(6):611-616. PubMed ID: 29910474 [TBL] [Abstract][Full Text] [Related]
9. In this issue - May 2019: West Nile virus in horses · Treating horses with dexamethasone via nebulisation · Animal hoarding in NSW · Dangers of powdered washing soda for emesis in dogs · Pneumocystis in a dog following toceranib phosphate · Oxalate nephrosis in koalas. Jackson AE Aust Vet J; 2019 May; 97(5):129-130. PubMed ID: 31025324 [No Abstract] [Full Text] [Related]
10. Phosphorylated KIT as a predictor of outcome in canine mast cell tumours treated with toceranib phosphate or vinblastine. Thamm DH; Weishaar KM; Charles JB; Ehrhart EJ Vet Comp Oncol; 2020 Jun; 18(2):169-175. PubMed ID: 31365175 [TBL] [Abstract][Full Text] [Related]
11. Presumptive primary intrathoracic mast cell tumours in two dogs. Cartagena-Albertus JC; Moise A; Moya-García S; Cámara-Fernández N; Montoya-Alonso JA BMC Vet Res; 2019 Jun; 15(1):204. PubMed ID: 31208404 [TBL] [Abstract][Full Text] [Related]
12. Pneumocystis carinii pneumonia in a Yorkshire terrier dog. Cabañes FJ; Roura X; Majó N; Bragulat MR; Domingo M Med Mycol; 2000 Dec; 38(6):451-3. PubMed ID: 11204883 [TBL] [Abstract][Full Text] [Related]
13. Palmar-plantar erythrodysesthesia syndrome resulting from toceranib phosphate in a dog with apocrine gland anal sac adenocarcinoma: a case report. Kim E; Kim SS; Ryu MO J Vet Sci; 2023 Nov; 24(6):e76. PubMed ID: 37904638 [TBL] [Abstract][Full Text] [Related]
14. Combination toceranib and lomustine shows frequent high grade toxicities when used for treatment of non-resectable or recurrent mast cell tumours in dogs: A European multicentre study. Bavcar S; de Vos J; Kessler M; de Fornel P; Buracco P; Murphy S; Hirschberger J; Argyle DJ Vet J; 2017 Jun; 224():1-6. PubMed ID: 28697868 [TBL] [Abstract][Full Text] [Related]
15. Safety evaluation of combination carboplatin and toceranib phosphate (Palladia) in tumour-bearing dogs: A phase I dose finding study. Wouda RM; Hocker SE; Higginbotham ML Vet Comp Oncol; 2018 Mar; 16(1):E52-E60. PubMed ID: 28799187 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose. Bernabe LF; Portela R; Nguyen S; Kisseberth WC; Pennell M; Yancey MF; London CA BMC Vet Res; 2013 Sep; 9():190. PubMed ID: 24079884 [TBL] [Abstract][Full Text] [Related]
17. Safety evaluation of combination toceranib phosphate (Palladia®) and piroxicam in tumour-bearing dogs (excluding mast cell tumours): a phase I dose-finding study. Chon E; McCartan L; Kubicek LN; Vail DM Vet Comp Oncol; 2012 Sep; 10(3):184-93. PubMed ID: 22235941 [TBL] [Abstract][Full Text] [Related]
18. Response and outcome following toceranib phosphate treatment for stage four anal sac apocrine gland adenocarcinoma in dogs: 15 cases (2013-2017). Elliott JW J Am Vet Med Assoc; 2019 Apr; 254(8):960-966. PubMed ID: 30938616 [TBL] [Abstract][Full Text] [Related]
19. Retrospective evaluation of canine heart base tumours treated with toceranib phosphate (Palladia): 2011-2018. Lew FH; McQuown B; Borrego J; Cunningham S; Burgess KE Vet Comp Oncol; 2019 Dec; 17(4):465-471. PubMed ID: 31069932 [TBL] [Abstract][Full Text] [Related]
20. Radiographic aspects of Pneumocystis carinii pneumonia in the miniature Dachshund. Kirberger RM; Lobetti RG Vet Radiol Ultrasound; 1998; 39(4):313-7. PubMed ID: 9710133 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]